|
1
|
Daneshmanesh AH, Hojjat-Farsangi M, Khan
AS, Jeddi- Tehrani M, Akhondi MM, Bayat AA, Ghods R, Mahmoudi AR,
Hadavi R, Österborg A, et al: Monoclonal antibodies against ROR1
induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
Leukemia. 26:1348–1355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shabani M, Naseri J and Shokri F: Receptor
tyrosine kinase-like orphan receptor 1: a novel target for cancer
immunotherapy. Expert Opin Ther Targets. 19:941–955. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baskar S, Kwong KY, Hofer T, Levy JM,
Kennedy MG, Lee E, Staudt LM, Wilson WH, Wiestner A and Rader C:
Unique cell surface expression of receptor tyrosine kinase ROR1 in
human B-cell chronic lymphocytic leukemia. Clin Cancer Res.
14:396–404. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barna G, Mihalik R, Timár B, Tömböl J,
Csende Z, Sebestyén A, Bödör C, Csernus B, Reiniger L, Peták I, et
al: ROR1 expression is not a unique marker of CLL. Hematol Oncol.
29:17–21. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang S, Chen L, Wang-Rodriguez J, Zhang
L, Cui B, Frankel W, Wu R and Kipps TJ: The onco-embryonic antigen
ROR1 is expressed by a variety of human cancers. Am J Pathol.
181:1903–1910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wurz GT, Kao CJ and DeGregorio MW: Novel
cancer antigens for personalized immunotherapies: latest evidence
and clinical potential. Ther Adv Med Oncol. 8:4–31. 2016.PubMed/NCBI
|
|
7
|
Uhrmacher S, Schmidt C, Erdfelder F,
Poll-Wolbeck SJ, Gehrke I, Hallek M and Kreuzer KA: Use of the
receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a
diagnostic tool in chronic lymphocytic leukemia (CLL). Leuk Res.
35:1360–1366. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ida L, Yamaguchi T, Yanagisawa K, Kajino
T, Shimada Y, Suzuki M and Takahashi T: Receptor tyrosine
kinase-like orphan receptor 1, a target of NKX2-1/TTF-1
lineage-survival oncogene, inhibits apoptosis signal-regulating
kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma.
Cancer Sci. 107:155–161. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang H, Qiu J, Ye C, Yang D, Gao L, Su Y,
Tang X, Xu N, Zhang D, Xiong L, Mao Y, Li F and Zhu J: ROR1
expression correlated with poor clinical outcome in human ovarian
cancer. Sci Rep. 4:58112014.PubMed/NCBI
|
|
10
|
Rosenwald A, Alizadeh AA, Widhopf G, Simon
R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, et
al: Relation of gene expression phenotype to immunoglobulin
mutation genotype in B cell chronic lymphocytic leukemia. J Exp
Med. 194:1639–1647. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Klein U, Tu Y, Stolovitzky GA, Mattioli M,
Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L,
et al: Gene expression profiling of B cell chronic lymphocytic
leukemia reveals a homogeneous phenotype related to memory B cells.
J Exp Med. 194:1625–1638. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Daneshmanesh AH, Mikaelsson E,
Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, Akhondi M,
Lagercrantz S, Larsson C, Osterborg A, et al: Ror1, a cell surface
receptor tyrosine kinase is expressed in chronic lymphocytic
leukemia and may serve as a putative target for therapy. Int J
Cancer. 123:1190–1195. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shabani M, Asgarian-Omran H, Vossough P,
Sharifian RA, Faranoush M, Ghragozlou S, Khoshnoodi J, Roohi A,
Jeddi-Tehrani M, Mellstedt H, et al: Expression profile of orphan
receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in
different subsets of B-cell acute lymphoblastic leukemia. Leuk
Lymphoma. 49:1360–1367. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shabani M, Asgarian-Omran H, Jeddi-Tehrani
M, Vossough P, Faranoush M, Sharifian RA, Toughe GR, Kordmahin M,
Khoshnoodi J, Roohi A, et al: Overexpression of orphan receptor
tyrosine kinase Ror1 as a putative tumor-associated antigen in
Iranian patients with acute lymphoblastic leukemia. Tumour Biol.
28:318–326. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang S, Chen L, Cui B, Chuang HY, Yu J,
Wang-Rodriguez J, Tang L, Chen G, Basak GW and Kipps TJ: ROR1 is
expressed in human breast cancer and associated with enhanced
tumor-cell growth. PLoS One. 7:e311272012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rabbani H, Ostadkarampour M, Manesh AH
Danesh, Basiri A, Jeddi-Tehrani M and Forouzesh F: Expression of
ROR1 in patients with renal cancer - a potential diagnostic marker.
Iran Biomed J. 14:77–82. 2010.PubMed/NCBI
|
|
17
|
O'Connell MP, Marchbank K, Webster MR,
Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q,
et al: Hypoxia induces phenotypic plasticity and therapy resistance
in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer
Discov. 3:1378–1393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hojjat-Farsangi M, Ghaemimanesh F,
Daneshmanesh AH, Bayat AA, Mahmoudian J, Jeddi-Tehrani M, Rabbani H
and Mellstedt H: Inhibition of the receptor tyrosine kinase ROR1 by
anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of
melanoma cells. PLoS One. 8:e611672013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shabani M, Omran H Asgarian, Farsangi MH,
Vossough P, Sharifian RA, Toughe GR, Razavi SM, Khoshnoodi J,
Jeddi-Tehrani M, Rabbani H, et al: Comparative expression profile
of orphan receptor tyrosine kinase ROR1 in Iranian patients with
lymphoid and myeloid leukemias. Avicenna J Med Biotechnol.
3:119–125. 2011.PubMed/NCBI
|
|
20
|
Daneshmanesh AH, Porwit A, Hojjat-Farsangi
M, Jeddi-Tehrani M, Tamm KP, Grandér D, Lehmann S, Norin S, Shokri
F, Rabbani H, et al: Orphan receptor tyrosine kinases ROR1 and ROR2
in hematological malignancies. Leuk Lymphoma. 54:843–850. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hojjat-Farsangi M, Khan AS, Daneshmanesh
AH, Moshfegh A, Sandin A, Mansouri L, Palma M, Lundin J, Österborg
A and Mellstedt H: The tyrosine kinase receptor ROR1 is
constitutively phosphorylated in chronic lymphocytic leukemia (CLL)
cells. PLoS One. 8:e783392013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Borcherding N, Kusner D, Liu GH and Zhang
W: ROR1, an embryonic protein with an emerging role in cancer
biology. Protein Cell. 5:496–502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li P, Harris D, Liu Z, Liu J, Keating M
and Estrov Z: Stat3 activates the receptor tyrosine kinase like
orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS
One. 5:e118592010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fukuda T, Chen L, Endo T, Tang L, Lu D,
Castro JE, Widhopf GF II, Rassenti LZ, Cantwell MJ, Prussak CE, et
al: Antisera induced by infusions of autologous Ad-CD154-leukemia B
cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.
Proc Natl Acad Sci USA. 105:3047–3052. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bicocca VT, Chang BH, Masouleh BK, Muschen
M, Loriaux MM, Druker BJ and Tyner JW: Crosstalk between ROR1 and
the Pre-B cell receptor promotes survival of t(1;19) acute
lymphoblastic leukemia. Cancer Cell. 22:656–667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamaguchi T, Yanagisawa K, Sugiyama R,
Hosono Y, Shimada Y, Arima C, Kato S, Tomida S, Suzuki M, Osada H,
et al: NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR
survival signaling in lung adenocarcinoma. Cancer Cell. 21:348–361.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cui B, Zhang S, Chen L, Yu J, Widhopf GF
II, Fecteau JF, Rassenti LZ and Kipps TJ: Targeting ROR1 inhibits
epithelial-mesenchymal transition and metastasis. Cancer Res.
73:3649–3660. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Graziano C: HER-2 breast assay, linked to
Herceptin, wins FDA's okay. CAP Today. 12(1): 14–16. 1998.
|
|
29
|
Herbst RS, Fukuoka M and Baselga J:
Gefitinib - a novel targeted approach to treating cancer. Nat Rev
Cancer. 4:956–965. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dowell J, Minna JD and Kirkpatrick P:
Erlotinib hydrochloride. Nat Rev Drug Discov. 4:13–14. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xia W, Mullin RJ, Keith BR, Liu LH, Ma H,
Rusnak DW, Owens G, Alligood KJ and Spector NL: Anti-tumor activity
of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation
of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene.
21:6255–6263. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rimawi MF, Wiechmann LS, Wang YC, Huang C,
Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G,
Massarweh S, et al: Reduced dose and intermittent treatment with
lapatinib and trastuzumab for potent blockade of the HER pathway in
HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res.
17:1351–1361. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yuan HH, Han Y, Bian WX, Liu L and Bai YX:
The effect of monoclonal antibody cetuximab (C225) in combination
with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer
cell lines. Pathology. 44:547–551. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guarneri V, Frassoldati A, Bottini A,
Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G,
Musolino A, et al: Preoperative chemotherapy plus trastuzumab,
lapatinib, or both in human epidermal growth factor receptor
2-positive operable breast cancer: results of the randomized phase
II CHER-LOB study. J Clin Oncol. 30:1989–1995. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang J, Baskar S, Kwong KY, Kennedy MG,
Wiestner A and Rader C: Therapeutic potential and challenges of
targeting receptor tyrosine kinase ROR1 with monoclonal antibodies
in B-cell malignancies. PLoS One. 6:e210182011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Widhopf GF II, Cui B, Ghia EM, Chen L,
Messer K, Shen Z, Briggs SP, Croce CM and Kipps TJ: ROR1 can
interact with TCL1 and enhance leukemogenesis in Eµ-TCL1 transgenic
mice. Proc Natl Acad Sci USA. 111:793–798. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cui B, Widhopf GF II, Prussak CE, Wu CCN,
Sadarangani A, Zhang S, Lao F, Jamieson CHM, Carson DA and Kipps
TJ: Cirmtuzumab vedotin (UC-961ADC3), an anti-ROR1-monomethyl
auristatin E antibody-drug conjugate, is a potential treatment for
ROR1-positive leukemia and solid tumors. Presented at 55th ASH
Annual Meeting. (abstract 1637). 2013; https://ash.confex.com/ash/2013/webprogram/Paper65533.html
|
|
38
|
Baskar S, Wiestner A, Wilson WH, Pastan I
and Rader C: Targeting malignant B cells with an immunotoxin
against ROR1. MAbs. 4:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gilbert JA: Lenalidomide as first-line
therapy for elderly CLL patients. Lancet Oncol. 14:e3452013.
View Article : Google Scholar
|
|
40
|
Hojjat-Farsangi M, Daneshmanesh AH,
Osterborg A, Shokri F and Mellstedt H: Patients with chronic
lymphocyte leukemia (CLL) have naturally occurring antibodies
against the receptor tyrosine kinase (ROR1). Blood (ASH Annual
Meeting abstracts). 118:17712011.
|
|
41
|
Yu J, Cui B, Widhopf GF II, Chen L,
Rassenti L, Wang Z, Ma S, Hayashi T, Carson DA and Kipps TJ:
Preclinical development of ROR1 peptide based vaccine with activity
against chroniclymphocytic leukemia in ROR1 transgenic mice. Blood
(ASH Annual Meeting abstracts). 122:41742013.
|
|
42
|
Milani A, Sangiolo D, Montemurro F,
Aglietta M and Valabrega G: Active immunotherapy in HER2
overexpressing breast cancer: current status and future
perspectives. Ann Oncol. 24:1740–1748. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hudecek M, Lupo-Stanghellini MT, Kosasih
PL, Sommermeyer D, Jensen MC, Rader C and Riddell SR: Receptor
affinity and extracellular domain modifications affect tumor
recognition by ROR1-specific chimeric antigen receptor T cells.
Clin Cancer Res. 19:3153–3164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Robertson SC, Tynan J and Donoghue DJ: RTK
mutations and human syndromes: when good receptors turn bad. Trends
Genet. 16:3682000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zwick E, Bange J and Ullrich A: Receptor
tyrosine kinase signalling as a target for cancer intervention
strategies. Endocr Relat Cancer. 8:161–173. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ghosh AK, Secreto C, Boysen J, Sassoon T,
Shanafelt TD, Mukhopadhyay D and Kay NE: The novel receptor
tyrosine kinase Axl is constitutively active in B-cell chronic
lymphocytic leukemia and acts as a docking site of nonreceptor
kinases: implications for therapy. Blood. 117:1928–1937. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Paesler J, Gehrke I, Gandhirajan RK,
Filipovich A, Hertweck M, Erdfelder F, Uhrmacher S, Poll-Wolbeck
SJ, Hallek M and Kreuzer KA: The vascular endothelial growth factor
receptor tyrosine kinase inhibitors vatalanib and pazopanib
potently induce apoptosis in chronic lymphocytic leukemia cells in
vitro and in vivo. Clin Cancer Res. 16:3390–3398. 2010. View Article : Google Scholar : PubMed/NCBI
|
